Celularity regains Nasdaq bid price and market value compliance; filing delay remains

Celularity Inc

Nasdaq confirmed compliance with Rule 5550(a)(2) bid price and Rule 5550(b)(2) market value requirements on Sept 11, 2026.
Listing Qualifications Staff closed both matters; no further action needed on those fronts.
Delayed filing deficiency under Rule 5250(c)(1) for periodic reports remains outstanding.
Company continues to work on completing delayed filings to regain full compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.